Thus, increasing cAMP by apremilast or inhibiting EGFR by erlotinib might be promising new treatment options for ACM patients since they were proven to be effective in enhancing desmosome integrity and, thereby, cell adhesion in different experimental models of ACM and pemphigus, as shown in this study and previous reports (Shoykhet, Dervishi et al. [48], Sigmund, Winkler et al. [50], Egu, Schmitt et al. [16]). The gene discussed is EGFR; the disease is pemphigus.